Novel dual-targeting approach to reshape tumor immunological profiles
Co-founded by Landmark BioVentures and OM Pharma, Duhn Therapeutics is well-positioned to leverage the collective expertise from seasoned innovators, drug developers and key opinion leaders to advance our novel platform of lipid-based cancer immunotherapies
Our mechanism of action specifically inhibits immunosuppressive mechanisms and activates the immune response with an initial focus on treating solid cancers associated with or resulting from chronic non-resolved immunosuppressive inflammation